Kyverna Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €146.17M +227.1% -€302.25M -∞% -206.8% -2.1 pp N/A N/A
    (estimated) €44.68M +142.7% N/A N/A N/A N/A
    (estimated) €18.41M +∞% -€217.04M +25.7% -1,179.1% -12 pp N/A N/A
    (estimated) €0.00 +NaN% -€172.73M +17.0% N/A -€166.57M +30.4% N/A
    (estimated) €0.00 +NaN% -€147.68M +34.3% N/A -€127.72M +32.1% N/A
    €0.00 +NaN% -€109.96M +111.2% N/A -€96.65M +116.3% N/A
    €0.00 -100.0% -€52.07M +108.9% N/A -€44.67M +46.5% N/A
    €6.06M +24.2% -€24.92M +9.7% -411.3% +0.55 pp -€30.49M +69.4% -503.1% -1.3 pp
    €4.88M -€22.73M -465.9% -€18.00M -368.9%

    Notifications